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Dear Ladies and Gentlemen,
As a representative of the German Federation of Diabetics
(Deutscher Diabetiker Bund) in North Rhine-Westphalia I
would like to communicate from the view of people
being involved in the disease diabetes, how and to
which scale Predictive, Preventive and Personalised
Medicine in Germany has a chance to be integrated into the
therapy of diseases.
Predictive Medicine
The German Federation of Diabetics believes that it is
meaningful for people, living under the risk of suffering
from a specific disease, to evaluate the risk factors more
precisely by means of Predictive Medicine. On the other
hand it might be ethically questionable to apply those
methods in cases, in which serious consequences (e.g.
death) can possibly be expected. For the patients this could
be a situation of extraordinary mental stress. In those cases
predictive methods or tests should only be applied, if a
patient has given an explicit mandate. In our opinion results
of such methods of testing should only be communicated to
the patient by qualified medical specialists.
However, when we are talking about disease patterns, in
which a patient’s behaviour, in combination with a qualified
therapy, could avoid a worsening of the disease, the chances
of Predictive Medicine should be employed.
Prevention
Prevention is not only a problem in our public healthcare
system but also a problem of our society in general. Despite
the fact that every third teenager carries the risk of diabetes
there is almost no effort in prevention. This is even worse
as genetic, family-related and socio-economic factors play a
critical role in the further growing up of the adolescent
persons. Hence prevention and working towards a healthy
lifestyle should already start on the pre-school level, for
example in the kindergarten or play school. The steadily
increasing number of children and adolescents suffering
from diabetes type 2 is significant. Normally information
about the disease diabetes and a healthy lifestyle does not
start before the manifestation of the disease took place.
Especially for those patients, carrying a high risk, special
risk-related measures of prevention should regularly be
taken.
Personalised Medicine
The German Federation of Diabetics expects considerable
success when PersonalisedMedicine is applied in the treatment
of serious and/or chronic diseases. In Germany the influence of
economic factors on political decisions on health care has been
growing. The legislative organs and self-governing bodies
impose strict regulations on doctors and therapists, which in
most cases only allow standardised treatment.
However, from our point of view individual treatment by
means of biomarkers provides a lot of advantages:
& Insufficient or even wrong treatment and therapies could
be avoided
& Risks or adverse reactions of pharmaceuticals and
therapies could be avoided or limited
& With individual treatment from the beginning, unnecessary
cost for insufficient or wrong treatment could be eliminated
& Patients could be protected from significant complica-
tions of the disease and also from cost.
POTENTIAL NEW STRATEGIES IN DIABETES
THERAPEUTICS
Sena CM
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The rising incidence of diabetes, metabolic syndrome, and
subsequent vascular diseases is a major public health
problem in industrialized countries. Diabetes is a progres-
sive disease with a complex pathophysiology that includes
peripheral insulin resistance, declining β-cell function and
mass, declining insulin secretion over time, inappropriate
glucagon secretion and hepatic glucose production, and
deficiencies in amylin and glucagon-like peptide (GLP-1).
The main pharmacological drugs that have been used in
the treatment of type 2 diabetes are: α-glucosidase
inhibitors, to delay intestinal carbohydrate absorption (e.
g. acarbose); biguanides to target hepatic insulin resistance
(e.g. metformin); insulin secretagogues or sulphonylureas,
to increase pancreatic insulin secretion and also increase
glucose-induced insulin secretion (e.g. glibenclamide;
gliclazide); insulin sensitisers or thiazolidinediones, to
target adipocyte and muscle insulin resistance (e.g.
troglitazone; rosiglitazone); and intestinal lipase inhibi-
tors, to inhibit fat absorption and promote weight loss in
obese patients (e.g. orlistat) (Figure).
Observational studies have found that bariatric surgery
is effective in patients with obesity and diabetes,
reinstating near normal glycaemia in 50–80% of patients
for several years. Bariatric surgery is now an accepted
treatment for obese patients with diabetes. The finding that
glycaemic control is promptly reinstated in most patients with
diabetes when less food passes through the stomach,
duodenum, and proximal jejunum—independently of the
amount of weight lost—has focused attention on research
into gastrointestinal factors as a potential source of new drugs
for the treatment of type 2 diabetes. Several gastrointestinal
peptides (includingGLP-1, glucose dependent insulinotrophic
polypeptide, and peptide YY) could provide a basis for new
treatments in patients with obesity and diabetes.
DPP-4 inhibitors and GLP-1 agonists stimulate glucose-
mediated insulin secretion from pancreatic β cells and
suppress glucagon release; GLP-1 agonists also delay
gastric emptying; and amylin agonists suppress gluca-
gon release and delay gastric emptying. Combination
therapy that includes drugs with complementary mech-
anisms of action is most effective and sometimes
preferred.
There is great potential for developing a new generation
of therapeutics that offer better control of diabetes, its
co-morbidities and its complications. This contribution
summarizes current pharmacological approaches to treat
diabetes mellitus and will focus on novel therapies for
diabetes mellitus that are under development. Potential
new treatments include analogues of intestinal and
adipocyte hormones, inhibitors of renal glucose reab-
sorption and cellular glucocorticoid activation, and
activators of cellular energy production.
INDICES OF DNA DAMAGE AS POTENTIAL
PREDICTIVE MARKERS OF DIABETIC
NEPHROPATHY
Mozaffari MS, Yao Liu J, El-Awady A, Baban B
Department of Oral Biology, College of Dental Medicine,
Georgia Health Sciences University, Augusta, Georgia 30912,
USA
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The world-wide epidemic of obesity has fueled the
increasing incidence of type 2 diabetes mellitus. In turn,
type 2 diabetes is associated with major target organ
complications with increased morbidity and mortality.
Indeed, nephropathy is a prominent complication of type
2 diabetes with end-stage renal failure which requires renal
dialysis and/or renal transplantation. It is, therefore,
imperative to identify novel diagnostic predictors for early
detection, and monitoring progression, of target organ
pathologies such as nephropathy. A hallmark feature of
type 2 diabetes mellitus is hyperglycemia-induced oxidative
stress and consequent DNA damage. Thus, identification of
indices of DNA injury that co-relate with disease progres-
sion and manifestation of target organ pathologies are
urgently needed. While the modified nucleoside, 8-
hydroxydeoxyguanosine (8-OHdG), is a useful index
of oxidative DNA damage, γH2AX has emerged has a
sensitive index of double-strand DNA (dsDNA) breaks,
the most severe form of DNA injury. Accordingly, the
focus of our recent studies was to examine the impact
of insulin resistance/type 2 diabetes mellitus on urinary
and/or renal tissue 8-OHdG and γH2AX utilizing two
highly relevant animal models of the disease, namely
the obese Zucker rat (OZR) and db/db mouse (and
their respective lean nondiabetic controls, LZR and db/
m, respectively); these animal models lack the leptin
receptor and thus are markedly obese, insulin resistant
and hyperglycemic. The OZR displayed mild hypergly-
cemia but marked hyperinsulinemia in association with
increased albuminuria compared to the lean controls.
Urinary excretion of 8-OHdG was significantly increased
in the OZR compared to LZR. Interestingly, however,
renal tissue of OZR revealed similar 8-OHdG immunos-
taining intensity and pattern to that of LZR. Subsequent
studies using the severely hyperglycemic obese diabetic
db/db mice revealed significant reduction in glomerular
function but marked albuminuria than their lean db/m
controls. Further, urinary excretion of 8-OHdG was
markedly increased in db/db, than db/m, group while
renal tissue 8-OHdG immunostaining was similar be-
tween the two groups. On the other hand, renal tissue of
db/db mice displayed increased nuclear γH2AX immu-
nostaining compared to the db/m group. Subsequent
Western blot analysis further confirmed increased renal
tissue γH2AX level in db/db mice. Collectively, the
results suggest that while urinary 8-OHdG excretion is a
helpful predictive marker of whole body oxidative DNA
damage, renal tissue 8-OHdG immunostaining is an
unlikely predictor of local oxidative DNA damage. On
the other hand, renal tissue γH2AX is a more likely
predictor of local DNA injury.
Supported by a grant from the National Institutes of Health.
RETINOPATHY SCREENING AS THE PROMOTER
OFPREDICTIVE, PREVENTIVEANDPERSONALISED
MEDICINE IN TYPE 2 DIABETES CARE
Salminen L
School of Medicine, University of Tampere, Finland
More than 75 % of patients who have diabetes mellitus for
more than 20 years develop a kind of diabetic retinopathy
(DR). In cohort studies, DR is prevented and treated
effectively by strict control of HbA1c, hypertension and
hypercholesterolaemia by lifestyle changes and medication.
In clinical practice, DR is one primary endpoint and maker
of suboptimal quality of diabetes treatment. DR is a leading
cause of visual impairment in working population. How-
ever, diabetes related vision loss is greatest in the elderly
with type 2 diabetes (T2D). Digital fundus photography by
accredited workforce, image grading, quality assurance and
IT considerations is the evidence based, sensitive and
specific method for DR screening and follow up. It is one
of the most cost effective health procedures to promote
timely treatment of patients with T2D from a public health
standpoint.
European countries differ considerably in type and quality
of T2D as well as DR prevention and treatments. It is
assumed that few countries have been able to increase
resources for eye health since Liverpool Declaration in
2005 (www.drscreening2005.org.uk). This contribution is
focused on numerical facts of T2D in Europe with incidence
and prevalence, prevention and care models. Factors like
personal health practices (exercise, self-care), psychosocial
(social support, internal locus of control), and healthcare use
(access to care, type of care provided, belief in the ability of
the healthcare system to help), diabetes registries, mass
implication of preventive guidelines and programs, elec-
tronic patient records with digital images are identified
and outlined and road mapped. The unique opportunity
of ophthalmologists to influence patient behavior and
inform patient’s primary care physician is stressed. It is
suggested that information technology and social media
will play a central role in the redesign of the healthcare
quality promoting predictive, preventive and personal-
ized medicine for patients with T2D.
VISUAL LOSS IN DIABETIC PATIENTS—DO WE
PREVENT IT OR DO WE TREAT ONLY
THE COMPLICATIONS?
Josifova T, Henrich PB, Cybulska A, Flammer J
University Hospital Basel, Eye Clinic
There are two main reasons of visual loss in patients
with diabetes: diabetic maculopathy (DM) and prolif-
erative diabetic retinopathy (PDR). The prevalence of
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PDR and DME is closely related to the duration of
diabetes. During a life-time more then 50% of patients
with type 2 diabetes develop visual loss, versus 1/3 of
patients with type 1 diabetes. Correlation between
blood glucose and presence of PDR, in absence of C
peptide determination is in close connection to the
development of retinopathy. Two initial therapeutic
approaches are up to date in the treatment of PDR.
The aim of the first one is to discourage proliferations,
and second—to prevent and relieve the contraction of
the fibroproliferative vitreoretinal membranes (Fig. 1).
Laser photocoagulation (LFK)—retinal burns is still the
“golden standard” in prevention and treatment of PDR.
Destruction of the new vessels required burns involve
the full thickness retina and often lead to nerve fiber
field defects. Although being treated with LFK, some
of the patients develop severe complications and
underwent surgical procedure. Recovery of good vision
after surgery in PDR in the early vitrectomy group is
observed only in 24.5% of the patients. The prevalence
of DM in type 2 diabetes after 5 years duration is
about 5% compared to 20% after 20 years of duration.
The classification of DM is: diabetic macular edema
(DME), ischaemic maculopathy and vitreomacular
interface changes. Improving the diagnostic techniques,
a lot of ongoing studies have investigated different
medications for intravitreal usage in conditions of
DME (Fig. 2). The grid LFK on the leaking micro-
aneurisams in combination with focal LFK is still one
of the important treatments of DME. Up to date
medications include the corticosteroids and Anti-
VEGF drugs. A lot of studies such as READ (Resolve,
Restore and DRCR.net Study Group) have summarised
the latest results. Improvement in findings does not
always match to visual acuity increase. The treatment of
the vitreomacular interface changes is surgical, but
without great improvement, and the changes are recur-
rent. There is no effective treatment for ischemic
macular changes, which are always associated with
severe visual loss. Despite a lot of investigations run,
there is still no any protocol elaborated for DME
treatment.
Considering the fact that about 26% of patients with type 1
and 36% type 2 diabetic patients have never had their eyes
examined, the risk for different ocular complications is very
high: 32% of patients with diabetes at high-risk for visual
loss never undergo an eye examination. When examined
almost 61% of these patients are found to have diabetic
retinopathy, cataract, glaucoma or other ocular pathologies.
In order to prevent the ocular diabetic complications,
healthcare and eye-care delivery system on a personal-
based level should be enhanced in societies. The only key
to success: focusing on “individuals” but not on “patients”
with already manifested disorders to apply innovative
investigation approaches in the general population and
groups at risk.
ANKLE—BRACHIAL INDEX IN TYPE 2 DIABETES
PATIENTS AND CARDIOVASCULAR RISK
Nussbaumerova B, Rosolova H, Sefrna F, Sipova I, Sifalda P
2nd Medical Department, Charles University in Prague—
Medical Faculty in Pilsen, Czech Republic
Purpose: The ankle—brachial index (ABI), i.e. the ratio of
systolic blood pressure (SBP) measured on the ankle and on
the arm, is considered the diagnostic parameter for the
Fig. 1 Fundus foto of a PDR with preretinal haemorrhage
Fig. 2 OCT finding of DME
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peripheral occlusive artery disease and the marker of
cardiovascular (CV) risk. We measured ABI in patients with
type 2 diabetes (DM2) and evaluated its impact on the CVrisk.
Method: A sample of 253 DM2 patients (135 males, 118
females, average age 66±9 y.) was examined. The supine
ankle SBP was measured with the Doppler ultrasonography
sond after a 5 minutes rest, with the 2 mmHg accuracy, SBP
on the identical arm was measured the same way with the
same accuracy by the mercury sphygmomanometer. The
ABI<0.9 suggests the arterial occlusion, on the contrary the
ABI ≥1.2 is nondiagnostic and suspected of mediocalci-
nosis. The CV risk was evaluated according to up-to-date
guidelines; as the high risk patients were considered the
patients with manifested CV diseases (information from the
patients’ documentation), with elevated coronary calcium
score (CAC) evaluated by the Agatston’s score (101–400
high risk, ≥401 very high risk) or according to the global
CV Risk Score≥5%. Used statistical method: Wilcoxon’s
unpaired test, χ2 test, Spearman’s correlation, multiple
logistic regression.
Results: The ABI<0.9 was found unilateral in 20 DM2 (8
%), bilateral in 27 (11%), thus the ABI was decreased in 47
(19%) DM2. Other 168 DM2 (66%) showed the normal
ABI and 38 (15%) the nondiagnostic ABI. There was no
significant difference in the characteristics of DM2 patients
with the normal and the nondiagnostic ABI. The DM2
patients with the ABI≤0.9 compared to the rest of the
sample were older males with elevated total cholesterol,
total homocystein and CAC and with the history of CV
diseases. Many CV and metabolic risk factors correlated
significantly positively with ABI<0.9: age, glycaemia, total
homocystein, CAC (p<0.05), LDL-cholesterol (p<0.01)
and SBP (p<0.01). The ABI<0.9 was significantly and
independently associated with age (p<0.001), smoking
(p<0.01), LDL-cholesterol, total homocystein and CAC
(p<0.05). The decreased ABI was a strong significant
predictor of ischemic stroke and symptomatic carotid
stenosis for the next 3 years (p<0.001). The ABI<0.9
correlated significantly neither with ultrasensitive C-reactive
protein nor with presence of the metabolic syndrome in
DM2.
Conclusion: Decreased ABI<0.9 was found in 19% of DM2
patients. It was in a significant and independent association
with age, smoking, LDL-cholesterol, total homocystein and
CAC.We evaluatedABI<0.9 as a strong predictor of ischemic
stroke and symptomatic carotid artery stenosis. That is why
these patients need an individual, complex and intensive
intervention. Nondiagnostic ABI values were found in 15% of
the sample; a high prevalence of mediocalcinosis in DM2
patients is suspected.
CHARACTERISTICS OF INFLAMMATION COMMON
TO BOTH DIABETES AND PERIODONTITIS:
ARE PREDICTIVE DIAGNOSIS AND TARGETED
PREVENTIVE MEASURES POSSIBLE?
Krishna R1, Hanes PJ2
1Department of Periodontics, Georgia Health Sciences
University, College of Dental Medicine, Augusta, GA
30912, USA
2Academic Affairs, Georgia Health Sciences University,
College of Dental Medicine, Augusta, GA 30912, USA
In 2001, an NIH workgroup standardized the definition of a
biomarker as “a characteristic that is objectively measured and
evaluated as an indicator of normal biological processes,
pathogenic processes, or pharmacologic responses to a thera-
peutic intervention”.
Diabetes has several effects on the oral cavity including
xerostomia, burning mouth, altered wound healing, and
increased incidence of periodontal diseases such as gingi-
vitis and periodontitis. Diabetes and periodontitis are
chronic inflammatory disorders that contribute to each
others’ severity and worsen each others’ prognosis. Studies
have shown that patients with diabetes are at increased risk
of developing periodontitis, and that diabetics with untreat-
ed periodontitis have more difficulty controlling serum
glucose. Although the primary etiology of periodontal
disease is the bacterial biofilm that is present on the surface
of the teeth, 50% of the tissue destruction is attributed to
host response.
Epidemiologic studies have shown a three to fourfold
increased risk for progressive periodontal destruction in
diabetic patients compared with individuals without diabe-
tes. The factors suggested to explain this relationship
include altered immunoinflammatory response to bacterial
pathogens, diminution of the formative aspects of connec-
tive tissue metabolism, impaired wound healing, microvas-
cular changes, and formation of advanced glycation end-
products. Periodontal treatment that reduces gingival
inflammation aids in the control of hyperglycemia.
Immune cell functions such as adherence, chemotaxis
and phagocytosis, and monocytes/macrophage cell line
that is hyper-responsive to bacterial antigens resulting in
increased production of pro-inflammatory cytokines IL-1β
and TNF-α.
Periodontitis is accompanied by gingival bleeding and the
production of an inflammatory exudate termed gingival
crevicular fluid (GCF) that arises from the inflamed
gingival tissues surrounding the teeth. GCF contains
byproducts of connective tissue degradation, enzymes
from host and bacterial cells, cytokines and other
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inflammatory mediators, and has been studied for screen-
ing blood glucose and for biomarkers of both diabetes and
periodontitis. Studies conducted to date suggest that
gingival crevicular fluid may be an acceptable substitute
for “finger stick” blood for determination of serum
glucose levels and may therefore be a useful screening
tool in the dental office. Although the ideal immune-
inflammatory biomarker is yet to be found, some of the
promising cytokines expressed in the GCF that are
elevated in both periodontitis and diabetes include IL-
1β, IL-6, PGE2, and VEGF. Further research is necessary
to clarify the usefulness of these potential biomarkers and
to likewise investigate additional cytokines which have to
be studied in this regard.
ENDOTHELIAL DYSFUNCTION IN DIABETES:
POTENTIAL APPLICATION OF CIRCULATING
MARKERS AS ADVANCED DIAGNOSTIC
AND PROGNOSTIC TOOLS
Abebe W, Mozaffari MS
Department of Oral Biology, College of Dental Medicine,
Georgia Health Sciences University, Augusta, Georgia,
USA
Diabetes mellitus is a common chronic metabolic
disease with a growing prevalence rate worldwide. It
is associated with vascular disorders, which contribute
to as high as 80% of the 3.2 million annual deaths
attributed to complications of diabetes. Endothelial
dysfunction plays a crucial and an initiating role in
vascular disorders in both type 1 and type 2 diabetes
and insulin resistance/prediabetes. In the majority of
diabetic cases, it precedes the development of overt
hyperglycemia and its consequent complications.
Assessing the status of the endothelium can serve as a
valuable early diagnostic and prognostic tool for
vascular diseases in diabetes. In human subjects,
endothelial function/dysfunction has been evaluated
using several in vivo techniques based on the measure-
ment of the functional consequences of endothelial
activity (i.e., relaxation/lumen size alterations in blood
vessels). The commonly utilized techniques in thisFig. 2 Gingival Crevicular fluid flow in a periodontal pocket
Fig. 3 Clinical presentation of periodontitis in patient with undiag-
nosed diabetes mellitus (type 1). History of multiple recurring
periodontal abscesses
Fig. 1 Histology of periodontitis lesion. Bacteria-induced inflammation has
resulted in loss of connective tissue attachment to the tooth, epithelial
migration, pocket formation, and loss of supporting bone.
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regard are plethysmography, ultrasound and/or doppler
designed to measure blood flow or lumen size in
coronary arteries and peripheral blood vessels (e.g.,
brachial arteries). While these techniques are used primarily for
research purposes, some of them appear to be clinically
relevant for a limited scope of endothelial evaluations.
However, certain limitations associated with the methods,
particularly as related to technical difficulties and costs, have
precluded their routine clinical applications.
Recently, a number of endothelial-derived circulating
markers have been found to more directly indicate the
status of the endothelium. The measurement of these
biomarkers in the circulation is relatively easier and less
costly. These potential circulating indicators include von
Willebrand factor, soluble thrombomodulin, soluble E-
selectin, asymmetric dimethylarginine, tissue plasminogen
activator and endothelial microparticles. While the relative
importance of each substance (or their combinations) for
endothelial evaluation is not clearly defined, in most cases,
the determination of these biomarkers has provided good
indications of endothelial damage/activation, as it occurs in
diabetes. However, the validity of measuring these bio-
markers for diagnosis and/or prognosis of endothelial
dysfunction and the associated vascular disorders in
diabetes has not yet been fully established for routine
clinical applications. Other potential indicators of endothe-
lial function/dysfunction in diabetes are circulating endo-
thelial cells and circulating endothelial progenitor cells.
However, only very few studies have investigated the
clinical application of these cellular biomarkers, suggesting
the limited availability of information on their usefulness
for diagnostic and/or prognostic purposes in human
patients. Taken together, currently, the issue of circulating
endothelial markers is an area of intense research interest
with the potential to result in the development of clinically
relevant assessment techniques of the status of the
endothelium and the vasculature. It is hoped that as more
research data become available, improved measurement of
circulating endothelial indicators will make it possible to
obtain valuable diagnostic and prognostic information on
vascular events in diabetes and related conditions for
routine clinical testing.
INFLAMMATORY MARKERS AS POTENTIAL
PREDICTIVE INDICATORS FOR DIABETIC
NEPHROPATHY
Baban B, El-Awady A, Yao Liu J, Mozaffari MS
Department of Oral Biology, College of Dental Medicine,
Georgia Health Sciences University, Augusta, Georgia
30912, USA
Inflammatory pathways have emerged as major contributing
mechanisms to the pathogenesis of insulin resistance/obesity/
type 2 diabetes mellitus and associated chronic compli-
cations such as nephropathy. Thus, indices of inflam-
mation that co-relate with disease progression could
serve as potential predictive markers for the manifesta-
tion of target organ pathologies. Accordingly, the focus
of our recent studies was to determine the impact of
insulin resistance/type 2 diabetes on urinary, renal tissue
and/or blood levels of inflammatory markers. For these
studies we used two highly relevant animal models of
the disease, namely the obese Zucker rat (OZR) and db/
db mouse (and their respective lean nondiabetic con-
trols, LZR and db/m, respectively); OZR and db/db
mice lack the leptin receptor and thus are markedly
obese, insulin resistant and hyperglycemic. The OZR
displayed mild hyperglycemia but marked hyperinsulinemia
in association with changes in urinary excretion and renal
tissue levels of inflammatory markers including a) increased
urinary monocyte chemoattractant protein-1 excretion and b)
increased renal tissue levels of cyclooxygenase-2 and inter-
cellular adhesion molecule-1 and c) increased renal tissue
CD68 immunostaining. Subsequent studies using the severely
hyperglycemic db/db mice revealed significant reduction in
glomerular function but marked albuminuria compared to their
lean db/m controls. Immunohistochemical studies revealed
increased expression of interleukin (IL)-6 and IL-17 in renal
tubules of db/db compared to their db/m controls. Flow
cytometry studies further confirmed pro-inflammatory changes
in db/db mice as indicated by increased IL-17 positive cells in
peripheral blood and renal cells of db/db than db/m mice; the
status of IL-23 is currently under investigation. Collectively,
the results indicate that urinary and/or tissue as well as blood
inflammatory markers can serve as potential predictive
indicators for progression of type 2 diabetic nephropathy.
Supported, in part, by a grant from the National Institutes of
Health.
DRUG DELIVERY SYSTEMS: ADVANCED
TECHNOLOGIES POTENTIALLYAPPLICABLE
IN PERSONALIZED TREATMENTS
Coelho JF, Ferreira PC, Alves P, Cordeiro R, Fonseca AC,
Góis JR, Gil MH
Department of Chemical Engineering, University of Coim-
bra, 3030–290 Coimbra, Portugal
Advanced drug delivery systems (DDS) present indubitable
benefits for drug administration. Over the past three
decades, new approaches have been suggested for the
development of novel carriers for drug delivery. In this
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presentation, general concepts and emerging research in this
field based on multidisciplinary approaches aiming to
create personalized treatment for a broad range of highly
prevalent diseases (e.g., cancer and diabetes) will be
presented. The information presented is organized in two
parts. The first part provides an overview on currently
available drug delivery technologies including a brief
history on the development of these systems and some of
the research strategies applied. The second part provides
information about the most advanced drug delivery devices
using stimuli responsive polymers. Their synthesis using
controlled-living radical polymerization strategy is pre-
sented. In a near future it is predictable the appearance of
new effective tailor-made DDS, resulting from knowledge
of different interdisciplinary sciences, in a perspective of
creating personalized medical solutions.
CANCER PREDISPOSITION IN DIABETICS: RISK
FACTORS CONSIDERED FOR PREDICTIVE
DIAGNOSTICS AND TARGETED PREVENTIVE
MEASURES
Cebioglu M, Schild HH, Golubnitschaja O
Department of Radiology, Rheinische Friedrich-Wilhelms-
University of Bonn, Bonn, Germany
Cancer-related mortality in diabetics
According to the current worldwide statistics, every 10
seconds one patient dies on Diabetes mellitus (DM) related
consequences. Once appeared, cancer outcomes have worse



































Fig. 1. Increased mortality of diabetics versus non-diabetics for single cancer types as documented for patients treated in USA in years 1982–
1998. Data taken from [1]
Fig—Overview of the polymers used in DDS
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The overall concept of cancer—predisposition
in diabetics
Diabetics may be highly predisposed to cancer develop-
ment specifically due to following contributors:
– strong stress factors (excessive metabolic alterations,
disturbed glucose/insulin homeostasis, hormonal deregu-
lation, insufficient detoxification) with consequently
excessive production of ROS.
– mitochondrial dysfunction with consequent low energy
production, insufficient repair capacity and accumu-
lating damage to both chromosomal and mitochondrial
DNA.
– high risk for infectious disorders with consequently
induced viral proto-oncogenic activity as well as
activity of particular pathogenic bacterial forms such
as Helicobacter pylori.
Adequacy of stress response, repair capacity as well as
immune defence are highly individual for each patient and
strongly depend on risk factors such as genetic background,
age, environmental factors, nutrition, body culture, life
style, etc.
Outlook
Current biotechnology possesses sufficient power to estimate
a severity of damage to sub-cellular structures, individual
stress reactions and repair capacity. For example, by
stress proteome profiling in peripheral leukocytes and
blood plasma, individual stress reactions can be well
estimated. Advanced predictive diagnostic approaches
are currently close to clinical application and allow to
select groups of risk and to estimate a predisposition to
severe complications in diabetics. Much attention should
be focused on targeted preventive arrangements in
diabetes care, in order to restrict or even avoid severe
secondary complications, such as cancer.
References
1. Cebioglu M, Schild HH, Lolubnitschaja O. Cancer predisposition in
diabetics: risk factors considered for predictive diagnostics and
targeted preventive measures. EPMA J. 2010;1:130–7.
BARIATRIC MEDICINE: MULTIDISCIPLINARY
APPROACH FOR OBESITY PREVENTION
Dimitrov DV
Medical University Varna, Varna, Bulgaria
Obesity and its associated diseases are epidemic that
represent a major threat to human health. In the last two
decades an explosive increase in the number of people
diagnosed with diabetes has been observed worldwide and
the global figure of affected individuals is expected to rise
from currently 250 million to 350 million in 2025. The
rapidly escalating number of affected patients at even very
young age poses a tremendous burden on the public health
system and a substantial reinforcement of research activities
including transnational cooperation between scientists from
different disciplines is urgently required to avoid a
socioeconomic disaster. Dietary interventions and pharma-
cological strategies, however, failed to deliver success, due
to side effects (e.g. sibutramine, rimonabant) or lack of
efficacy (e.g. lorcaserin, recombinant leptin). For patients
with obesity and type 2 diabetes, bariatric surgery is by far
the most effective treatment—it is, indeed, the only form of
treatment that can put patients into full long-term remission.
This contribution reviews rise and fall of anti-obesity
treatments and highlights the importance of bariatric
surgery as the only way to cut diabetes costs at present.
We discuss also public health implications. Until a
successful non-surgical means for preventing and reversing
obesity is developed, bariatric surgery appears to be the
only intervention that can result in a sustained reversal of
both obesity and type 2 diabetes mellitus in most patients
receiving it. One of the key recommendations is the need
for a multidisciplinary bariatric team to oversee the ongoing
needs of patients after surgery, as well as to build a weight
maintenance program. Beside surgeon, such bariatric
medicine team should include metabolic physicians,
nutritionists, physical activities specialists, cardiologists, etc.
MSCS AS TOOLS FOR RESTORING
MORPHOFUNCTIONAL DEFICIENCY
AND MODULATING IMMUNE RESPONSES
AT THE PRECLINICAL STAGE OF T1D:
MILESTONES AND HANDICAPS
Kostyushev DS1, Paltsev MA2, Suchkov SV1,3
1I.M. Sechenov First Moscow State Medical University,
Moscow, Russia
2National Research Center “Kurchatov Institute”, Moscow,
Russia
3Moscow State Medical Dentistry University, Moscow,
Russia
Type 1 Diabetes (T1D) is a progressive autoimmune
disease associated with reduction of beta cell mass and,
as a consequence, metabolic disturbances in peripheral
blood glucose levels. Early diagnosis of T1D at the pre-
diabetic stage allows for timely implementation of
efficient preventive and predictive measures including
cell-based technologies aimed at stabilization of the
patient’s immune status and reseeding the pancreas with
newly formed beta cells. Mesenchymal Stem Cells
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(MSCs) are among the most promising therapeutic tools
for repairing the architectonics of the pancreas through
secretion of a vast majority of paracrine factors or
directed trans-differentiation into beta cells. In addition,
MSCs improve immune responses by acting upon the T cell
link of immunity (increasing the population of CD4+CD25+
FoxP3+ Tregs and Th2 and decreasing the population of
Th1), prevent the presentation of antigens by expressing
negative co-stimulatory molecules (PD-L1, PD-L2),
induce revascularization of the pancreas and afford
effective anti-apoptotic protection of beta cells. The
most promising approaches to isolation of MSCs, their
targeted delivery by directed homing, effects of secreted
soluble factors on pancreas regeneration and ways to
increase the proliferative activity of MSCs through
induction of expression of a vast array of humoral
factors are considered. The totality of experimental data
on tumorogenesis in animal models after MSCs injec-
tion is discussed in terms of their significance and
possibility of their extrapolation to human beings. This
contribution deals with the most promising approaches
to preventing malignant growth in human beings
following MSCs injection.
POLYMORPHIC GENETIC MARKERS
ARE OF SIGNIFICANCE FOR MONITORING
OF DISEASE PROGRESSION IN METABOLIC
SYNDROME PATIENTS
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Background: The metabolic syndrome (MS) is a cluster of
metabolic abnormalities, such as abdominal obesity, arterial
hypertension, and atherogenic dyslipidaemia, which are
associated with development of secondary complications
such as type 2 diabetes (DM2). Recently, many studies
showed pathology-specific polymorphisms in apolipopro-
tein genes that might be associated with the development of
DM2.
Objective: To study a possible association of several
polymorphisms of apo-genes APOA1 G-75A, APOA1
C83T, APOC3 Sst1, APOE epsilon, APOA5 T-1131C, and
APOA5 S19W with DM2 in MS patients.
Study population: MS patients with DM2, including 100
males and 264 females, average age 50.9±0.5, and
controls, including 114 healthy males (average age 40.0±0.5)
and 84 females (average age 85.9±0.5). All of them
were examined clinically, biochemically and genetically.
Results: Among male MS patients with DM2, there was a
higher rate of carries of APOE e2-allele compared to the
controls (22% vs. 13%, p=0.067). In addition, male
patients demonstrated a higher rate of carries of APOA5
19W-allele compared to the controls (13% vs. 3%, p=
0.005). There was not a significant difference in genotype
distribution of the studied apo-genes between female
groups. All studied groups were shown to correspond to
Hardy-Weinberg equilibrium.
Conclusion: Gender (male) is considered as a risk factor in
a diseases progression. Our results suggest that the APOE
and APOA5 S19W polymorphisms are of significance in
male patients with DM2.
ASSOCIATION OF ACE I AND FABP2 GENES
POLYMORPHISM IN CASES WITH TYPE-2
DIABETES MELLITUS IN NORTHERN INDIA
Mahdi F1, Banerjee D1, Rizvi N3, Sapkota R2, Saxena S3,
Khan NA2, Raza ST1
1Era’s Lucknow Medical College & Hospital, Lucknow, India.
2Baba Farid Institute of Technology, Dehradun, India.
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Background: India has the world’s largest diabetes
population with an estimated 50.8 million people living
with type 2 Diabetes Mellitus. Type 2 DM can shorten
the normal lifespan of an individual by up to one-fifth
and is a complex disorder accounting for 90–95% of all
diabetes syndromes. Diabetes mellitus has a major
impact on the cardiovascular and renal system, with
the main cause of death being directly related to
cardiovascular disease.
Angiotensin Converting Enzyme (ACE I), a key enzyme in
the renin-agiotensin system, is a zinc metallopeptidase,
which catalyses the conversion of Angiotensin I to
Angiotensin II, a potent vasoconstrictor, and through
protease activity it also inactivates bradykinin, a potent
vasodilator. Insertion/deletion (I/D) polymorphism of a
287 bp Alu repeat sequence in intron 16 of the ACE gene
is strongly associated with plasma and cellular ACE levels
and it indicates that the polymorphism may modulate the
expression of the ACE gene.
Fatty acid–binding protein (FABP2) is involved in the
transport and metabolism of saturated and unsaturated long-
chain fatty acids. The FABP2 gene has been proposed as a
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candidate gene for diabetes because the protein it codes for
is involved in Fatty Acid absorption and metabolism and
therefore, affect insulin sensitivity and glucose metabolism.
The Ala54Thr polymorphism is the most extensively
studied FABP2 variant, as this variant seems the most
likely candidate to alter the protein’s function.
Material &Methods: Polymerase Chain Reaction—Restriction
Fragment Length Polymorphism (PCR-RFLP) andGenotyping
was done to determine the ACE and FABP2 gene
polymorphism in 75 cases and 57 controls.
Results: The mean age of cases (n=75) in the study group
was (48.29±11.89) years while in the control group (n=57)
was (31.03±7.38) years. The frequencies of the genotypes
DD, ID and II in the T2DM group were 16%, 55% and
29% respectively while in the control group these frequen-
cies were 20%, 78% and 2 %. The frequency of I and D
allele in the T2DM patients group was 57% and 43%
respectively as compared to 51% and 49% in the controls.
I/D genotype were significantly more frequent in healthy
controls while I/I genotype occurred with significantly
more frequency in patients with T2DM.The frequencies of
the genotypes Ala54Ala, Ala54Thr and Thr54Thr in the
T2DM group were 17%, 63% and 20% respectively while
in the control group these frequencies were 23%, 63% and
14%. The frequency of Ala54 and Thr54 allele in the
T2DM patients group was 48% and 52% respectively as
compared to 54% and 46% in the controls. FABP2 gene
polymorphism shows no significant difference in Geno-
types and allele frequencies found in cases and controls.
Conclusion: It seems that the I/I allele frequency of ACE I/
D gene polymorphism was significant in the T2DM cases
as compared to controls. While the FABP2 gene polymor-
phism shows no significant difference in Genotypes and
allele frequencies found in cases and controls. It might be
recommended that ACE gene I/D polymorphisms can be a
good marker for the early identification of population at
risk of Type 2 diabetes mellitus.
MEASUREMENT OFANGIOGENESIS PROMOTORS
AND CYTOKINES CONCENTRATIONS
IN INTRAOCULAR FLUID OF PATIENTS
WITH PROLIFERATIVE DIABETIC RETINOPATHY
FORTREATMENT TAILORING POSSIBILITY
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Introduction: Proliferative Diabetic Retinopathy (PDR) is
the most common diabetic eye disease. It is caused by
pathology-specific changes in the blood vessels of the retina.
It is a leading cause of blindness in adults that can affect both
central and peripheral vision. Vision loss can be reduced by
timely diagnosis and treatment. Nowadays ophthalmology is
based on determination of status quo solely by visual control
or imaging techniques. Our aim was to prove the suitability of
multiplex analysis for measurement of changes of cytokines
and angiogenetic factors in intraocular fluid of patients with
proliferative diabetic retinopathy (PDR) and to determine its
clinical applicability for a potential use in ocular medicine.
Patient cohort: Patients with proliferative diabetic retinopa-
thy, patients with retinal detachment and control group of
patients before cataract surgery without any ocular pathology
were examined.
Methods: Intraocular fluid samples were aspirated from
anterior chamber of patients with PDR.
Concentrations of IL8, VEGF, EGF, IL 6, IP10, MCP1,
PDGF, Rantes, BDNF, CNTF TGFb1 and IL 10 were
measured simultaneously in intraocular fluid using multi-
plex panel kits from Millipore (USA) and Luminex 100
instrument (Luminex corp., USA). Levels of biomarkers
were compared between groups by Wilcoxon test and ROC
analysis was performed.
Results: We were able to detect levels of EGF, IL6,
VEGF, BDNF, CNTF, IL8, IP10, MCP1, PDGF AA, and
TGFb. In PDR patients, VEGF and other angiogenetic factors
and antiangiogenetic factor (IP 10) were found to be higher in
intraocular fluid compare to controls. In retinal detachment
patients, intraoccular levels of inflammatory markers were
observed to be higher compare to controls.
Conclusion: Multiplex analysis enables an easy simulta-
neous measurement of multiple markers in a very small
sample volume and so enables the use of biomarker
analyses in intraocular fluid as a standard method.
Support: Study was supported by the study project
NS10251-3.
NUTRITION OF PACIENTS WITH DIABETES
MELLITUS TYPE 2 IN RELATION WITH
SMOKING ADICTION—SURVEY POST-MONICA
2008/2009 IN CZECH REPUBLIC
Galovcová M, Adámková V, Cífková R, Petržílková Z,
Bruthans J, Lánská V
Department of Preventive Cardiology, Institute for Clinical
and Experimental Medicine, Prague
Introduction: Tobacco smoking is one of the most important
risk factors for cardiovascular disease (CVD). Smokers have
2-fold higher risk of coronary heart disease, 95% contributes
to a higher incidence of peripheral arterial disease. Smoking
affects not only alone, but synergistically with other risk
factors that potentiate the overall effect. The combination of
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smoking diabetics is a particular risk factor. However, stop
smoking is not a simple process: the main role plays strong
motivation. Some smokers argue with weight reduction. Are
smoking diabetics really slimmer?
Objective: To compare nutritional parameters in smokers and
nonsmokers diabetics type 2.
Methods: 1% random population sample aged 25–64 years
was selected from nine districts of the Czech Republic. The
examination consisted of completing a standard question-
naire, obtaining major anthropometric data, repeated blood
pressure measurements, and blood sampling.
Results: We examined 3612 persons, whom 250 were type
2 diabetics from.
The experimental group included 162 (64.8%) male and 88
(35.2%) femal diabetics.
Therefrom, smokers were 52 (32%) men and 20 (23%)
women. The average age of smokers was 54.4 ±8.6 years
and 56.6 ±7.0 years of non-smokers (p<0,05).
SMOKERS NON-SMOKERS P
Age 54.4±8.6 56.6±7.0 *
sBP 136.8±19.6 138.9±20.0 n.s.
dBP 84.3±11.6 82.8±10.2 n.s.
BMI 31.8±6.1 33.1±5.8 n.s.
Waist 105.9±14.6 108.0±13.6 n.s.
TC 5.0±1.2 5.2±1.4 n.s.
TAG 2.4±1.6 2.4±1.9 n.s.
HDL-chol. 1.2±0.4 1.2±0.3 n.s.
LDL-chol. 2.8±1.0 3.0±1.1 n.s.
Glucose 8.6±3.0 9.1±3.0 n.s.
We found no indication that smoking diabetics have smaller
BMI and waist. However, both groups demonstrated poorly
controlled diabetes and higher blood pressure compared to
non-smoking diabetics.
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